Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-012134
Filing Date
2024-08-14
Accepted
2024-08-14 07:02:59
Documents
55
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q plx-20240630x10q.htm   iXBRL 10-Q 1072218
2 EX-31.1 plx-20240630xex31d1.htm EX-31.1 12568
3 EX-31.2 plx-20240630xex31d2.htm EX-31.2 12737
4 EX-32.1 plx-20240630xex32d1.htm EX-32.1 6808
5 EX-32.2 plx-20240630xex32d2.htm EX-32.2 6830
6 GRAPHIC plx-20240630x10q005.jpg GRAPHIC 113104
7 GRAPHIC plx-20240630x10q007.jpg GRAPHIC 100730
8 GRAPHIC plx-20240630x10q008.jpg GRAPHIC 61840
  Complete submission text file 0001558370-24-012134.txt   5000196

Data Files

Seq Description Document Type Size
9 EX-101.SCH plx-20240630.xsd EX-101.SCH 32225
10 EX-101.CAL plx-20240630_cal.xml EX-101.CAL 39428
11 EX-101.DEF plx-20240630_def.xml EX-101.DEF 124586
12 EX-101.LAB plx-20240630_lab.xml EX-101.LAB 226532
13 EX-101.PRE plx-20240630_pre.xml EX-101.PRE 201153
58 EXTRACTED XBRL INSTANCE DOCUMENT plx-20240630x10q_htm.xml XML 564699
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 241204094
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)